These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 34587552)

  • 1. State of the CAR-T: Risk of Infections with Chimeric Antigen Receptor T-Cell Therapy and Determinants of SARS-CoV-2 Vaccine Responses.
    Meir J; Abid MA; Abid MB
    Transplant Cell Ther; 2021 Dec; 27(12):973-987. PubMed ID: 34587552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis.
    Abid MB; Rubin M; Szabo A; Longo W; Fenske TS; McCoy C; Lorge A; Abedin S; D'Souza A; Dhakal B; Shah NN; Hamadani M
    Transplant Cell Ther; 2024 Mar; 30(3):285-297. PubMed ID: 38142942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.
    McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy.
    Infante MS; Nemirovsky D; Devlin S; DeWolf S; Tamari R; Dahi PB; Lee YJ; Chung DJ; Politikos I; Barker J; Giralt SA; Babady NE; Ramanathan L; Papanicolaou GA; Seo S; Kamboj M; Perales MA; Shah GL
    Transplant Cell Ther; 2024 Jan; 30(1):116.e1-116.e12. PubMed ID: 37806446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients.
    Wu X; Wang L; Shen L; He L; Tang K
    J Hematol Oncol; 2022 Jun; 15(1):81. PubMed ID: 35710431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunologic responses to the third and fourth doses of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in cell therapy recipients: a systematic review and meta-analysis.
    Sharifi Aliabadi L; Azari M; Taherian MR; Barkhordar M; Abbas SAM; Azari M; Ahmadvand M; Salehi Z; Rouzbahani S; Vaezi M
    Virol J; 2024 May; 21(1):103. PubMed ID: 38702752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
    Khawaja F; Papanicolaou G; Dadwal S; Pergam SA; Wingard JR; Boghdadly ZE; Abidi MZ; Waghmare A; Shahid Z; Michaels L; Hill JA; Kamboj M; Boeckh M; Auletta JJ; Chemaly RF
    Transplant Cell Ther; 2023 Jan; 29(1):10-18. PubMed ID: 36273782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.
    Wei J; Zhao J; Han M; Meng F; Zhou J
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
    Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
    Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immunogenicity of the seasonal influenza vaccine before and after CAR-T-cell therapy: a prospective observational study.
    Walti CS; Loes AN; Shuey K; Krantz EM; Boonyaratanakornkit J; Keane-Candib J; Loeffelholz T; Wolf CR; Taylor JJ; Gardner RA; Green DJ; Cowan AJ; Maloney DG; Turtle CJ; Pergam SA; Chu HY; Bloom JD; Hill JA
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34702753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy.
    Chiuppesi F; Ortega-Francisco S; Gutierrez MA; Li J; Ly M; Faircloth K; Mack-Onyeike J; La Rosa C; Thomas S; Zhou Q; Drake J; Slape C; Fernando P; Rida W; Kaltcheva T; Grifoni A; Sette A; Patterson A; Dempsey S; Ball B; Ali H; Salhotra A; Stein A; Nathwani N; Rosenzweig M; Nikolaenko L; Al Malki MM; Dickter J; Nanayakkara DD; Puing A; Forman SJ; Taplitz RA; Zaia JA; Nakamura R; Wussow F; Diamond DJ; Dadwal SS
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B-cell malignancies and COVID-19: a narrative review.
    Luque-Paz D; Sesques P; Wallet F; Bachy E; Ader F;
    Clin Microbiol Infect; 2023 Mar; 29(3):332-337. PubMed ID: 36336236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
    J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma.
    Wiedmeier-Nutor JE; Iqbal M; Rosenthal AC; Bezerra ED; Garcia-Robledo JE; Bansal R; Johnston PB; Hathcock M; Larsen JT; Bergsagel PL; Wang Y; Reeder CB; Leis JF; Fonseca R; Palmer JM; Gysbers BJ; Mwangi R; Warsame RM; Kourelis T; Hayman SR; Dingli D; Kapoor P; Kumar SK; Durani U; Villasboas JC; Paludo J; Bennani NN; Nowakowski G; Ansell SM; Castro JE; Kharfan-Dabaja MA; Lin Y; Vergidis P; Murthy HS; Munoz J
    Clin Lymphoma Myeloma Leuk; 2023 Jun; 23(6):456-462. PubMed ID: 37003846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 vaccine response in CAR T-cell therapy recipients: A systematic review and preliminary observations.
    Abid MA; Abid MB
    Hematol Oncol; 2022 Apr; 40(2):287-291. PubMed ID: 34911142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature.
    Mercadal S; Gomez CA; Lee CJ; Couriel DR
    Ann Hematol; 2023 Jul; 102(7):1837-1843. PubMed ID: 37246975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101).
    Hill JA; Martens MJ; Young JH; Bhavsar K; Kou J; Chen M; Lee LW; Baluch A; Dhodapkar MV; Nakamura R; Peyton K; Howard DS; Ibrahim U; Shahid Z; Armistead P; Westervelt P; McCarty J; McGuirk J; Hamadani M; DeWolf S; Hosszu K; Sharon E; Spahn A; Toor AA; Waldvogel S; Greenberger LM; Auletta JJ; Horowitz MM; Riches ML; Perales MA
    medRxiv; 2024 Jan; ():. PubMed ID: 38343800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy.
    Wudhikarn K; Perales MA
    Bone Marrow Transplant; 2022 Oct; 57(10):1477-1488. PubMed ID: 35840746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.